Bayer To Build Web Of Hemophilia Treatment Centers Across China
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Bayer Schering Pharma is partnering with the Chinese Society of Hematology to build a network of hemophilia treatment centers that will crisscross China, according to a Bayer executive in Asia
You may also be interested in...
Biosimilars Might Ultimately Lower Economic Barriers To Treatment For Hemophiliac Youths In Asia
BEIJING - Although sporadic advances in treating hemophilia are being led by scientists and state health officials across pockets of Asia, including inside China, most of the people afflicted with the genetic blood disorder on the planet's most populous continent will die while still children, according to a leading authority on the disease
Biosimilars Might Ultimately Lower Economic Barriers To Treatment For Hemophiliac Youths In Asia
BEIJING - Although sporadic advances in treating hemophilia are being led by scientists and state health officials across pockets of Asia, including inside China, most of the people afflicted with the genetic blood disorder on the planet's most populous continent will die while still children, according to a leading authority on the disease
Bayer Schering Strengthens Presence In South Korea
SEOUL - Bayer Schering Pharma plans to upgrade its current seventh position in South Korea's pharma market to become one of three leading multinational companies in coming years, Bayer execs told reporters at a Nov. 27 press conference in Seoul